Program

radionuklidterapi.se

 

David Ulmert

MSKCC

Targeting Secreted Antigens

for Precision Imaging and Therapy

Anders Bjartell Johannes Czernin

Lund University UCLA

Prostate Cancer Imaging with a purpose:

– clinical challenge From Diagnostics to Theranostics

Program

15-17 November 2017

(Preliminary titles, exact times are in the PDF program)

Wednesday

Registration starts at 12.00, scientific program at 13.00.

 

Special theme: Prostate Cancer Theranostics

 

 

 

Konferensen 2017 hölls i föreläsningssalen i nya Strålningsbehandlingshuset, Klinikgatan 5, Lund.

Michael Laßmann Kalevi Kairemo

University Hospital Docrates Cancer Center

Würzburg Helsinki

Dosimetry in Prostate PSMA Prostanostics in Clinical

Cancer therapy Routine

 

 

 

 

 

 

Friday

 

 

Susan Evans-Axelsson, Lund University

Establishing 177Lu-PSMA-617 radioligand therapy in syngeneic in vivo models of prostate cancer

 

Oskar Vilhelmsson-Timmermand, Lund University

Radioimmunotherapy efficacy assessment of an internalizing humanized antibody: a systemic and tumor micro dosimetry perspective on a secreted antigen, human kallikrein-related peptidase 2, targeted in prostate cancer

 

Jens Ceder, Lund University

Stem cells in Prostate Cancer

 

Snacks and drinks will be served after the session.

Thursday

Full day scientific program.

 

 

 

 

 

Michael Lassmann presenting work by Uta Eberlein, Würzburg Universityl

Biological Dosimetry in Nuclear Medicine

 

Magnus Gram, Lund University

α1-microglobulin (A1M) - a radical scavenger with potential to be used for radiation protection

 

Jonas Ahlstedt, Lund University

Protection of kidney function with human recombinant α1-microglobulin (A1M) in a mouse radiation therapy model

 

Lovisa Lundholm. Stockholms university

The role of chromatin in response to alpha and gamma radiation in breast cancer cells

 

Linn Hagmarker, Gothenburg University

Evaluation of the correlations between the absorbed bone marrow dose and bone marrow response during the first cycle of 177Lu-DOTATATE treatment

 

Britta Langen, Gothenburg University

Age and sex: important variables in biomarker discovery for radiotherapy and risk estimation

 

Bertil Persson, Lund University

The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer

 

Sören Mattsson and Katarina Sjögreen Gleisner, Lund University

Ongoing work on radionuclide therapy dosimetry in EANM, ICRP, ICRU och IAEA

 

Anders Örbom, Lund University

Intratumoral activity distribution over time in preclincal radioimmunotherapy models

 

Katarina Sjögreen Gleisner, Lund University

Lund-Göteborg NET study

 

Emma Mellhammar, Lund University

ET in preclinical intratherapy monitoring

 

Pontus Kjellman, Lund University

Targeted Nanoparticles for theranostics of prostate cancer

 

Maria Evertsson, Lund University

Magnetomotive ultrasound imaging - a new tool for cancer diagnosis

 

Renata Madru, Lund University

Simultaneous preclinical PET-MRI study of lymphatic drainage of chelator free 64Cu-labeled nanoparticles

 

Emma Wikberg, Sahlgrenska University Hospital

Comparison of an analysis method and visual assessment concerning liver metastases in 111In-octreotide SPECT imaging including Monte Carlo based reconstruction

 

Daniel Roth, Lund University

A method for 177Lu-PRRT tumour dosimetry based on hybrid planar-SPECT/CT images and semi-automatic segmentation

 

Tom Bäck, Gotheburg University

High-resolution Alpha Camera imaging as a tool for developing Targeted Alpha Therapy

 

Lunch will be served and a Conference Dinner held in the evening.

 

Friday

Scientific program until 13.00.

 

Tomas Ohlsson, Lund University

Radiochemistry and Cyclotron produced radionuclides

 

Anja Mortensen, Uppsala University

Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

 

Mohamed Altai, Uppsala University

Affibody-based PNA-mediated pretargeted therapy

 

Mats Lindroos, Lund University

Introduction to the European Spallation Source ESS

 

Martin Beck, Lund University

MAX IV – Synchrotron Light Source

 

Johannes Czernin, UCLA

JNMMI Editors view on future research and publications

Magnus Dahlbom

UCLA

New developements in SPECT and PET

Copyright @ All Rights Reserved